title: Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies.
abstract: Cytomegalovirus (CMV) infection is a major complication of BMT. The oral cavity is a common route for CMV infection, whose protection is provided by salivary anti-CMV antibodies. We developed an ELISA assay for the detection of CMV-specific antibodies in parotid saliva. Saliva of patients receiving BMT from CMV-positive donors was transiently reconstituted with IgG and IgA anti-CMV antibodies shortly after transplantation. The concentration of these antibodies gradually decreased during the 2 months after transplantation and increased again around day 80. A remarkable rise in the salivary concentrations of IgG and IgM anti-CMV was observed shortly after i.v. administration of Sandoglobulin. These results demonstrate, for the first time accurate monitoring of CMV-specific antibodies in saliva using a quantitative ELISA assay. The study suggests that secretion of CMV-specific antibodies in saliva of immunocompromised patients can be reconstituted by donor-derived B and plasma cells transferred with the BM or by i.v. administration of pooled Ig.
authors.affiliation: Lautenberg Center of General and Tumor Immunology, Hebrew University-Hadassah School of Dental Medicine, Jerusalem, Israel.
authors.forename: G
authors.initials: G
authors.lastname: Chaushu
authors.forename: S
authors.initials: S
authors.lastname: Chaushu
authors.forename: S
authors.initials: S
authors.lastname: Slavin
authors.forename: R
authors.initials: R
authors.lastname: Or
authors.forename: A A
authors.initials: AA
authors.lastname: Garfunkel
authors.forename: E
authors.initials: E
authors.lastname: Yefenof
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis* / Q000097:blood; D000918:Antibody Specificity; D001402:B-Lymphocytes / Q000637:transplantation; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology*; D002648:Child; D003587:Cytomegalovirus / Q000276:immunology* / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control / Q000635:transmission; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000032:analysis* / Q000097:blood / Q000276:immunology; D007075:Immunoglobulin M / Q000032:analysis* / Q000097:blood / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010306:Parotid Gland / Q000378:metabolism; D010950:Plasma Cells / Q000637:transplantation; D012463:Saliva / Q000276:immunology*; D012471:Salivary Proteins and Peptides / Q000032:analysis*; D013997:Time Factors; D014775:Virus Activation
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; D012471:Salivary Proteins and Peptides